Brintellix® was discovered by Lundbeck researchers in Copenhagen, Denmark. Brintellix® was first approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorders in 2013 and is currently being marketed in more than 70 countries and regions in the world, including the United States and the European Union. Brintellix® was formally approved by the China State Food and Drug Administration (CFDA) on November 21, 2017. Extensive clinical studies have demonstrated that Brintellix® not only helps to improve the emotional symptoms but also has a unique action in improving the cognitive symptoms of the MDD patients’ ability to regain functional recovery.